Loading today’s stories
Invest1 distinct publisher2 min readUpdated
Seven of eight new Seoul listings sit below their offer prices. The books cleared on day one; the damage arrived in the weeks after, which is a pricing-power problem rather than a valuation one.
The Investor · Invest desk
Compiled by The InvestorSomething wrong?How this is made
A cohort that closes its first session an average of 2.96% above offer has, in the narrow sense, been priced about right [5]. The book cleared. What happened next is the problem: measured from that average first-day close, Korea's third-quarter class has given up roughly 27% [2]. The error was not the indicative range. It was the assumption that a second layer of buyers would turn up above it.
In the second quarter that assumption paid. Three of the eight second-quarter debutants (MakinaRocks, Poled and Cosmo Robotics) closed day one at four times the offer price [8], and analysts cited by Seoul Economic Daily tie that to subscription money chasing a KOSPI that rose 68% in the quarter, with sentiment freezing once the index corrected [9]. Between the two quarters, average first-day performance moved about 130 percentage points [5].
The figure underwriters should be working from is the relative one. The third-quarter group came in six points behind the KOSPI and twelve behind the KOSDAQ, the venue where most of them listed [1]. New issues did not hold up as separate stories through the correction; they were the highest-beta way to own it. That is what a shareholder register full of allocation buyers does when the pop fails to arrive.
The individual names read the same way. HLGenomics closed its first day 31% below offer and now sits 57% below [6][4], a further 26 points after the market had already had its say on price [4]. Lemon Healthcare, which listed on the KOSDAQ on July 6 and finished its debut 6% under offer, is 48% below [6][4]. Dealicious is down 46% [4]. That shape of selling is supply meeting an absent bid, not a reaction to company news.
The rule change works on the other side of the ledger. The Financial Services Commission and the Korea Exchange published a draft on duplicate listings on July 6 and a final version on July 31 [10], and Seoul Economic Daily reports that the firming of those rules added to the wait-and-see mood in the market [13]. That thins the pipeline; it does nothing for the bid.
Goodai Global and Musinsa are being weighed as candidates [15]. Any book built on second-quarter comparables is quoting a market that only existed inside a 68% index rally [9].
Follow any of these and your For You feed starts watching them — no settings page required.
Ranked by verification strength, evidence, and original report placement.
The Korea Exchange said on August 23 that, based on closing prices as of August 21, the eight companies newly listed on the KOSPI and KOSDAQ since July, excluding REITs and SPACs, had fallen an average of 25% from their offering prices.
Over the same period the KOSPI fell 19% and the KOSDAQ fell 13%.
Seven of the eight new listings traded below their offering prices, with Ingenia Therapeutics the only exception.
HLGenomics recorded the largest decline at 57% below its offering price, followed by Lemon Healthcare at 48% and Dealicious at 46%.
The eight third-quarter debutants rose an average of 2.96% on their opening day of trading.
Four of the eight fell below their offering prices on the first day: Lemon Healthcare, which listed on the KOSDAQ on July 6, closed 6% below offer; HLGenomics, which listed on July 24, fell 31%; Dealicious and Kido Industrial, both of which listed in August, fell 27% and 35%.
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Specific exchange-sourced figures, relayed by a single publisher
The core quantitative claims are precise, dated and attributed to the Korea Exchange (cohort definition, measurement date, index comparators, named issuers with individual declines), and the derived arithmetic is internally consistent. Evidence is capped well below high because there is exactly one source item and one publisher in the cluster, no primary KRX document or dataset is linked, all attribution for causation is to unnamed 'analysts', and the regulatory chill assertion has no supporting instance.
Real completed transactions and an in-force rulebook, thin forward pipeline
This is not a proposal but realized market activity: eight completed listings with observable offer prices, debut closes and current prices; a finalized FSC/KRX duplicate-listing regime published July 31; and one filed preliminary review request. The score is held back because the forward pipeline is mostly speculative (Goodai Global and Musinsa are 'possibilities'), and no filing counts, withdrawal counts or deal-value totals are given to size issuer behavior after the correction.
Reporting is drier than the data warrants
The article's language stays close to its numbers and even softens the finding ('rose an average of just 2.96%', 'some expect the mood could reverse'), while the underlying data describe an approximately 130-point swing in average debut performance in one quarter and a cohort needing roughly a 33% gain to reach offer price. The most consequential structural point — that books cleared and the loss came in the weeks after listing — is left implicit rather than asserted, so claims sit modestly below the evidence. The gap is small and negative, not large, because the single unevidenced causal assertion about duplicate-listing rules pushes the other way.
Neutral exchange data with a lightly promotional pipeline coda
The bulk of the piece relays Korea Exchange statistics that cut against the venue's own commercial interest, which is a low-incentive posture. Incentive pressure enters at the close, where an unattributed 'some expect the mood could reverse' frames named prospective issuers — Sono International, Goodai Global, Musinsa — in a way that serves deal-pipeline sentiment, and causal explanation rests on unnamed analysts whose affiliations and positions are undisclosed. No sponsorship, ownership or underwriting relationship is disclosed in the supplied material, so nothing higher can be substantiated.
Numbers trustworthy, interpretation single-threaded
Confidence in the offer-relative performance figures is reasonably high because they are dated, exchange-attributed and issuer-level checkable, and the derived arithmetic follows from them directly. Confidence in the interpretation is materially lower: one publisher, no primary document, unnamed analyst causation, no book-building, flow or lock-up data to distinguish a pricing-power problem from a broad beta drawdown, and one asserted regulatory effect with no supporting instance.
invest
Korea's 'patriot stocks' round-trip in five weeks, and the buyers were not who you think1 distinct publisher
invest
Korea's biggest fund houses answer 91 trading halts with bonds, gold and covered calls1 distinct publisher
invest
Korean chip large-caps take the lead back, and the KOSDAQ's August looks borrowed1 distinct publisher
invest
A 40 Trillion Won Buyback Is Holding Up the KOSPI, and the KOSDAQ Is Paying For It1 distinct publisher
Distinct publishers with included, body-backed reporting in this cluster.
en.sedaily.com
1 article · August 22, 2026